Citations

Clear

171 citation(s) found for "Moss, M".

Left Ventricular Entry to Reduce Brain Lesions During Catheter Ablation: A Randomized Trial
Marcus, Gregory M. , Tung, Roderick , Gerstenfeld, Edward P. , Hue, Trisha F. , Lin, Feng , Cheng, Jing , Weiss, J. Peter , Tzou, Wendy S. , Hsia, Henry H. , Ehdaie, Ashkan , Cooper, Daniel H. , Bunch, T. Jared , Arkles, Jeffrey , Lee, Adam , Hadjis, Alexios , Nguyen, Duy T. , Chelu, Mihail G. , Valderrábano, Miguel , Bhave, Prashant D. , Beaser, Andrew D. , Kanagasundram, Arvindh N. , Wazni, Oussama M. , Bradfield, Jason S. , Wall, Grace, Chang, Kathleen , Yang, Michelle, Montenegro, Gabrielle, Jarrott, Sabrina, Kramer, Joel H. , Kim, Anthony , Morris, Yonca, Dillon, W.P. , Hsia, Henry , Nazer, Babak , Lee, Adam , Hadjis, Alexios , Chelu, Mihail G , Hsu, Jonathan C , Valderrábano, Miguel , Bhave, Prashant D , Beaser, Andrew D , Kanagasundram, Arvindh , Wazni, Oussama , Chang, Kathleen , Jarrott, Sabrina , Kim, Anthony S , Dillon, William P , Tzou, Wendy , Weiss, Peter J , Marcus, Gregory M , Moss, Joshua D. , Hsu, Jonathan C. , Montenegro, Gabrielle C , Morris, Yvonne M.

Mayo Clinic

Circulation | February 24, 2025 | Volume: 151 | Issue: 15 | Pages: 1051-1059

10.1161/circulationaha.124.071352 | PMID 39989365 Get It

BACKGROUND: Catheter ablation of ventricular arrhythmias, one of the most rapidly growing procedures in cardiac electrophysiology, is associated with magnetic resonance imaging–detected brain lesions in more than half of cases. Although a retrograde aortic approach is conventional, modern tools enable entry through a transseptal approach that may avoid embolization of debris from the arterial system. We sought to test the hypothesis that a transseptal puncture would mitigate brain injury compared with a retrograde aortic approach. METHODS: The TRAVERSE trial (Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli) was a multicenter randomized controlled comparative effectiveness trial. Patients with left ventricular arrhythmias undergoing catheter ablation procedures were randomly assigned to a transseptal puncture approach compared (1:1) with a retrograde aortic approach. The primary outcome was the presence of an acute brain lesion detected by magnetic resonance imaging. Secondary outcomes included clinically manifest complications, procedural efficacy, and 6-month neurocognitive assessments. RESULTS: Among the 62 patients randomly assigned to a retrograde aortic approach with postoperative brain magnetic resonance imaging, 28 (45%) exhibited an acute brain lesion compared with 19 of the 69 (28%) of those randomized to a transseptal puncture ( P =0.036). No differences in clinically manifest complications or procedural efficacy were observed. More patients in the retrograde aortic arm were categorized as having a high likelihood of cognitive impairment at 6 months (33% compared with 19% of those in the transseptal arm), but substantial loss to follow-up was present. CONCLUSIONS: Among patients undergoing left ventricular catheter ablation procedures, a transseptal approach reduced the risk of acute brain lesions by nearly half compared with a retrograde aortic approach without sacrificing safety or efficacy. Given a likely embolic pathogenesis, the brain magnetic resonance imaging findings may reflect a propensity to other organ damage; these findings may extend to other procedures requiring left ventricular entry. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03946072.
The influence of prestroke disability on outcome in patients with a low Alberta Stroke Program Early CT Score who underwent endovascular thrombectomy
Uchida, Kazutaka , Maier, Ilko , Jabbour, Pascal , Kim, Joon-Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos , Grossberg, Jonathan A , Tanweer, Omar , Mascitelli, Justin, Polifka, Adam , Crosa, Roberto , Park, Min S. , Brinjikji, Waleed , Williamson, Richard , Kan, Peter , Chowdhry, Shakeel , Ezzeldin, Mohamad , Spiotta, Alejandro M , Crosa, Roberto , Wolfe, Stacey Quintero , Fragata, Isabel , Matsukawa, Hidetoshi , Elawady, Sameh Samir , Cunningham, Conor M. , Sowlat, Mohammad‐Mahdi , Jabbour, Pascal , Samaniego, Edgar A , Arthur, Adam Stephen , Yoshimura, Shinichi , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Matouk, Charles , Levitt, Michael R. , Moss, Mark, Navía, Pedro , Leacy, Reade De

Mayo Clinic

Journal of Neurosurgery | February 7, 2025 | Volume: 143 | Issue: 1 | Pages: 266-273

10.3171/2024.10.jns24888 | PMID 39919282 Get It

OBJECTIVE The definitive influence of prestroke disability on outcomes in patients with a low Alberta Stroke Program Early CT Score (ASPECTS) treated with endovascular thrombectomy (EVT) for acute ischemic stroke (AIS) due to large-vessel occlusion (LVO) remains unknown. This study aimed to investigate the impact of prestroke disability on outcomes in this specific population. METHODS Data from 32 international centers for AIS-LVO patients with a low ASPECTS who underwent EVT between January 2013 and December 2022 were analyzed retrospectively. Low ASPECTS and prestroke disability were defined as ASPECTS values of 2–5 and prestroke modified Rankin Scale (mRS) score ≥ 2. The primary outcome was a return to the prestroke mRS score at 90 days. Secondary outcomes were independent ambulation (mRS scores of 0–3) or a return to the prestroke mRS score at 90 days, good functional outcome (mRS scores of 0–2) or a return to the prestroke mRS score at 90 days, successful recanalization, and 90-day mortality. Safety outcomes were any intracranial hemorrhage or symptomatic intracranial hemorrhage. A symptomatic intracranial hemorrhage was defined as an intracranial hemorrhage with an associated worsening of ≥ 4 points in the National Institutes of Health Stroke Scale score. Outcomes were compared between patients with and without prestroke disability. RESULTS Of 293 patients, 50 (17.1%) had a prestroke disability. Of 50 patients, 20 (40.0%), 24 (48.0%), and 6 (12.0%) had prestroke mRS scores of 2, 3, and 4, respectively. The primary outcome showed no significant difference between the two groups. Compared with patients without prestroke disability, those with prestroke disability had a significantly smaller proportion of independent ambulation or return to prestroke mRS score (adjusted OR 0.13, 95% CI 0.03–0.53) and good functional outcome or return to prestroke mRS score (adjusted OR 0.21, 95% CI 0.05–0.91). Other secondary and safety outcomes showed no significant difference between the two groups. CONCLUSIONS The present study indicated that prestroke disability was not associated with a return to the prestroke mRS score at 90 days or intracranial hemorrhage. Physicians should not routinely exclude AIS-LVO patients with a low ASPECTS who have prestroke disability from EVT based on prestroke disability alone.
The Utility of Follow-up Transthoracic Echocardiogram to Screen for Severe Portopulmonary Hypertension (POPH) in Patients Granted POPH Model for End-stage Liver Disease (MELD) Exceptions
Kay, Dana , Krowka, Michael J. , Runo, James , Sadd, Corey J. , Cartin‐Ceba, Rodrigo , Cajigas, Héctor , Moss, John E. , Cajigas, Hector R , Valle, Kathryn T. del , Heimbach, Julie K. , Burger, Charles D. , DuBrock, Hilary M.

Mayo Clinic

Transplantation Direct | February 7, 2025 | Volume: 11 | Issue: 3 | Pages: e1757

10.1097/txd.0000000000001757 | PMID 39936134 Get It

Background. The current model for end-stage liver disease (MELD) exception policies for portopulmonary hypertension (POPH) require serial right heart catheterizations (RHCs) every 3 mo to maintain exception points. RHC is necessary for the initial diagnosis of POPH, but the utility of serial catheterizations has not been studied. In patients with POPH MELD exceptions, we sought to compare noninvasive and invasive hemodynamics and determine the sensitivity of echocardiography for the detection of hemodynamically severe POPH that would preclude liver transplant. Methods. We performed a single-center retrospective cohort study of patients with POPH MELD exceptions who underwent liver transplant from December 2008 to January 2024. Results were validated at an external center. Echocardiograms and RHCs performed within 1 mo were compared. Pearson correlation coefficient and Bland-Altman plots assessed the association between echocardiogram and RHC variables. We examined varied echocardiographic parameters to optimize sensitivity for the detection of hemodynamically severe POPH. Results. Twenty-two individuals underwent 60 follow-up RHCs with paired echocardiograms. Right ventricular systolic pressure (RVSP) and cardiac index estimated with echocardiogram were not strongly correlated with RHC measurements at follow-up (RVSP and RHC pulmonary artery systolic pressure: R = 0.30, P = 0.02; cardiac index: R = 0.17, P = 0.21). However, echocardiograms with RVSP ≥48 mm Hg had 100% sensitivity for detecting hemodynamically severe POPH, with 100% negative predictive value. In external validation of 13 paired echocardiograms and RHCs, our algorithm had 64% specificity and 100% negative predictive value. Conclusions. Although echocardiogram and RHC hemodynamic estimates were not strongly correlated, these results could potentially negate the current requirement for repeat RHC every 3 mo to maintain POPH MELD exception.
Comparative efficacy and safety of stent retrievers as a bailout strategy following failed contact aspiration technique in acute stroke thrombectomy
Ezzeldin, Mohamad , Hukamdad, Mishaal , Kasem, Rahim Abo , Ezzeldin, Rime , Maier, Ilko , Rai, Ansaar , Jabbour, Pascal , Kim, Joon‐Tae , Howard, Brian M. , Wolfe, Stacey Q , Starke, Robert M., Psychogios, Marios‐Nikos , Dye, Justin , Alaraj, Ali , Yoshimura, Shinichi, Tanweer, Omar , Navía, Pedro , Polifka, Adam , Siddiqui, Fazeel , Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard A., Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Chaubal, Varun , Spiotta, Alejandro M , Abo Kasem, Rahim , Rai, Ansaar , Wolfe, Stacey Quintero , Shaban, Amir , Alaraj, Ali , Fiorella, David , Navia, Pedro , Cuellar-Saenz, Hugo H , Fragata, Isabel , Mascitelli, Justin R , Osbun, Joshua W , Mokin, Maxim , Matouk, Charles , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Levitt, Michael R , Grandhi, Ramesh , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Howard, Brian M , Jabbour, Pascal , Alawieh, Ali , Goyal, Nitin , Fiorella, David , Romano, Daniele G, Cuellar, Hugo , Fragata, Isabel , Moss, Mark, Limaye, Kaustubh , Matouk, Charles , Park, Min S, Williamson, Richard, Levitt, Michael R. , Grandhi, Ramesh

Mayo Clinic

Journal of NeuroInterventional Surgery | January 30, 2025 | Volume: 18 | Issue: 2 | Pages: 390-398

10.1136/jnis-2024-022781 | PMID 39884851 Get It

Background The contact aspiration (CA) technique is often used to perform endovascular thrombectomy (EVT) for acute ischemic stroke (AIS); however, rescue strategies are necessary if CA fails to achieve recanalization. This study investigates the outcomes of incorporating stent retriever (SR) thrombectomy in the rescue strategy following failed CA. Methods EVT patients with failed CA attempts were identified from a large multicenter registry and stratified by rescue technique: CA alone or incorporating SR in the rescue strategy. Outcomes included successful recanalization, 90-day functional outcomes (defined by the modified Rankin Scale (mRS) score), symptomatic intracranial hemorrhage (sICH), and 90-day mortality. Results Among 1885 patients with failed CA attempts, conversion to SR was associated with higher recanalization rates (85.2% vs 80.6%; p=0.03), higher rates of second-pass recanalization (31.2% vs 23.4%; p<0.001), and better 90-day outcomes (mRS 0–2: 35.2% vs 29.9%; p=0.04) when compared with repeated CA attempts. Trevo SRs showed higher odds of successful recanalization (adjusted odds ratio (aOR)=1.9; p=0.02), second-pass recanalization (aOR=1.7; p=0.01), and reduced odds of sICH (aOR=0.3; p=0.02). EmboTrap SRs were associated with higher odds of 90-day mortality (aOR=2.6; p=0.004) and sICH (aOR=2.9; p=0.04) and lower odds of recanalization (aOR=0.5; p=0.03). Conclusions Incorporating SR in the rescue strategy after a failed CA improves recanalization rates and functional outcomes. Trevo SRs demonstrated superior efficacy and safety when incorporated into the rescue strategy.
Improved Outcomes and Resource Use With Normothermic Machine Perfusion in Liver Transplantation
Zhang, Chi , Li, Xingjie , Ohara, Stephanie , Kumm, Kayla , Cosentino, Christopher P., Aqel, Bashar , Frasco, Peter E. , Nunez-Nateras, Raphael, Hewitt, Winston R. , Harbell, Jack W. , Singer, Andrew L., Moss, Adyr A. , Reddy, Kunam S. , Mathur, Amit K. , Kumm, Kayla R, Lizaola-Mayo, Blanca C, Nguyen, Michelle , Chang, Yu‐Hui , Aqel, Bashar A. , Lizaola‐Mayo, Blanca , Nunez-Nateras, Raphael, Katariya, Nitin , Jadlowiec, Caroline C.

Mayo Clinic

JAMA Surgery | January 29, 2025 | Volume: 160 | Issue: 3 | Pages: 322

10.1001/jamasurg.2024.6520 | PMID 39878966 Get It

Importance Normothermic machine perfusion (NMP) has been shown to reduce peritransplant complications. Despite increasing NMP use in liver transplant (LT), there is a scarcity of real-world clinical experience data. Objective To compare LT outcomes between donation after brain death (DBD) and donation after circulatory death (DCD) allografts preserved with NMP or static cold storage (SCS). Design, Setting, and Participants This single-center, retrospective observational cohort study included all consecutive adult LTs performed between January 2019 and December 2023 at the Mayo Clinic in Arizona. Data analysis was performed between February 2024 and June 2024. Outcomes of DBD-SCS, DBD-NMP, DCD-SCS, and DCD-NMP transplants were compared. Exposure DBD and DCD livers preserved on NMP or SCS. Main Outcomes and Measures The primary outcomes were early allograft dysfunction (EAD), intraoperative transfusion, and post-LT hospital resource use, including length of stay (LOS) and readmissions. Secondary outcomes included acute kidney injury (AKI) and 1-year graft and patient survival. Results A total of 1086 LTs were included in the following 4 groups: DBD-SCS (n = 480), DBD-NMP (n = 63), DCD-SCS (n = 264), and DCD-NMP (n = 279). Among LT recipients, median (IQR) age was 60.0 years (52.0-66.0); 399 LT recipients (36.7%) were female. DCD-NMP had the lowest EAD rate (17.5%), followed by DCD-SCS (50.0%), DBD-NMP (36.8%), and DBD-SCS (27.3%) ( P &amp;lt; .001). DCD-NMP had the lowest intraoperative transfusion requirement compared to all other groups. Hospital and intensive care unit (ICU) LOS were shortest in DCD-NMP (median [IQR] hospital LOS, 5.0 days [4.0-7.0]; P = .01; median [IQR] ICU LOS, 1.5 days [1.2-3.1]; P = .01). One-year cumulative readmission probability was 86% lower for DCD-NMP vs DCD-SCS (95% CI, 0.09-0.22; P &amp;lt; .001) and 53% lower for DBD-NMP vs DBD-SCS (95% CI, 0.26-0.87; P &amp;lt; .001). AKI events were lower in DCD-NMP (31.1%) vs DCD-SCS (47.4%) ( P = .001). Compared to SCS, the NMP group had a 78% overall reduction in graft failure (hazard ratio [HR], 0.22; 95% CI, 0.10-0.49; P &amp;lt; .001). For those receiving DCD allografts, the risk reduction was even more pronounced, with an 87% decrease in graft failure (HR, 0.13; 95% CI, 0.05-0.33; P &amp;lt; .001). NMP was significantly protective from patient mortality vs SCS (HR, 0.31; 95% CI, 0.12-0.80; P = .02). Conclusions and Relevance In this observational high-volume cohort study, NMP significantly improved LT clinical outcomes and reduced hospital resource use, especially in DCD allografts. NMP may enhance access to LT by addressing the challenges historically linked with DCD liver use.
EVALUATING IN-HOME ASSISTIVE TECHNOLOGY FOR DEMENTIA CAREGIVERS: CHALLENGES AND OPPORTUNITIES
Chen, Kuan‐Hua , Scheffer, Julian A. , Merrilees, Jennifer , Hinderberger, Brian, Wang, Gene, Levenson, Robert W. , Levenson, Robert W , Yee, Claire , Moss, David

Mayo Clinic

Innovation in Aging | January 1, 2025 | Volume: 8 | Issue: Supplement_1 | Pages: 435-435

10.1093/geroni/igae098.1415 Get It

Abstract Dementia caregivers are at heightened risk for developing mental and physical health problems. Interventions designed to protect caregiver health often create additional demands on time and energy (e.g., exercise programs). Technology-based interventions (e.g., remote monitoring) can be effective, scalable, and do not add greatly to caregiver burden. Through a collaboration with a local technology company, Care Daily, we conducted two randomized controlled trials to evaluate People Power Caregiver (PPCg), a system of sensors in the home connected to cloud-based AI that alerts caregivers about worrisome deviations from normal patterns (e.g., care-recipient’s falls, wandering). Across two studies (study 1: 9-month duration with professional installation of PPCg; study 2: 6-month duration with caregiver self-installing the PPCg using remote tech support), 284 caregivers were recruited; 261 completed initial study deployment (e.g., system installation); and 235 completed the entire study protocol. Use of PPCg was associated with (a) reduced caregiver anxiety in study 1; (b) greater protection from declines in sleep efficiency in studies 1 and 2. These findings underscore the promise of technology-based intervention to mitigate health problems in dementia caregivers. However, challenges and complexities in recruitment (e.g., remote consenting both caregivers and care recipients), retention (e.g., due to changes in home environment or caregiving status), system installation (e.g., working with caregivers with less experience using technology), data quality assurance (e.g., invalid sensor data) as well as our efforts to overcome these challenges have been instructive. Lessons learned from these studies can provide useful guidance for future large-scale, technology-based interventions for dementia caregivers.
Recent advances in neuro-ophthalmology
Newman, Nancy J., Chen, John J. , Mollan, Susan P. , Moss, Heather E. , Miléa, Dan , Tisavipat, Nanthaya Yui, Chen, John J , Moss, Heather E , Bassi, Shikha Talwar , Newman, Nancy J. , Tisavipat, Nanthaya

Mayo Clinic

Indian Journal of Ophthalmology | December 30, 2024 | Volume: 72 | Issue: 11 | Pages: 1544-1559

10.4103/ijo.ijo_594_24 | PMID 39462921 Get It

This review article represents a collaborative effort across continents, bringing together the latest developments in neuro-ophthalmology with a focus on innovative diagnostic and therapeutic modalities that are shaping the future of the field. Among the most significant advancements is the rise of optical coherence tomography (OCT), now recognized as an indispensable tool in neuro-ophthalmological research, providing unparalleled insights into optic nerve and central nervous system pathologies. Gene therapy, particularly for conditions such as Leber's hereditary optic neuropathy, marks a new frontier in personalized medicine, offering hope for previously untreatable conditions. The article also examines the transformative role of telemedicine and artificial intelligence (AI) in clinical practice, which are revolutionizing patient care and enhancing diagnostic precision. Furthermore, it highlights the impact of novel serological biomarkers on the understanding and management of immune-mediated optic neuritis, and discusses the introduction of new therapeutic agents like Tocilizumab and Teprotumumab, which are redefining treatment paradigms. Collectively, these advancements reflect the profound influence of modern medicine on neuro-ophthalmology, paving the way for improved patient outcomes and fostering new avenues for research and clinical practice.
CTIM-14. EARLY SAFETY DATA FROM A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PHASE 2B STUDY OF IGV-001, AN AUTOLOGOUS CELL IMMUNOTHERAPY, VERSUS PLACEBO, IN NEWLY DIAGNOSED GLIOBLASTOMA (NDGBM)
Elder, J. Bradley , Hanft, Simon , Lee, Ian , Farrell, Christopher , Boockvar, John A. , Kim, Lyndon, Schulder, Michael , Correia, Carlos Eduardo Silva , Ramakrishna, Rohan , Wu, Julian K. , Agarwal, Vijay , Amankulor, Nduka, Evans, Linton T. , Giglio, Pierre , Wu, Kyle C., Wu, Synphen H., Falo, Cristina, Walbert, Tobias , Robin, Adam , Alnahhas, Iyad , Wernicke, A. Gabriella , Aregawi, Dawit , Maurer, Robert, Jeyapalan, Suriya, Magge, Rajiv , Chan, Amy B. W. , Hormigo, Adı́lia , Higgins, Dominique , Moss, Nelson S. , Sherman, Wendy, Neese, Leila, Pennock, Gregory, Scott, Charles , Perez-Olle, Raul , Andrews, David W. , Lee, Ian Y , Zacharia, Brad E. , Wong, Eric T. , Amankulor, Nduka, Bhatia, Ankush , Brennan, Cameron , Gill, Brian J. A. , Sengupta, Soma , ReFaey, Karim , Vojnic, Morana , Ghatan, Saadi , Singer, Samuel , Malik, Athar N. , Patel, Nitesh V. , Chan, Amy, IWAMOTO, FABIO MASSAITI , Dey, Mahua , Neese, Leila

Mayo Clinic

Neuro-Oncology | November 11, 2024 | Volume: 26 | Issue: Supplement_8 | Pages: viii88-viii88

10.1093/neuonc/noae165.0347 Get It

Abstract Standard of care (SOC) for ndGBM begins with maximal safe resection followed by adjuvant radiotherapy and temozolomide, and maintenance temozolomide. IGV-001 is an autologous biologic-device combination immunotherapy for the treatment of ndGBM that consists of autologous GBM tumor cells and an antisense oligonucleotide against IGF-1R mRNA, irradiated and administered via biodiffusion chambers implanted in the abdomen. In a phase 1b study, IGV-001 was well tolerated without unexpected adverse events in subjects with ndGBM. Multiple efficacy signals were observed, including significant improvements in progression-free survival (PFS), overall survival (OS), radiographic evidence of tumor response, and changes in immune response biomarkers. Here, we present early safety data from the phase 2b randomized, multicenter, double-blind, placebo-controlled study (NCT04485949) designed to assess efficacy and safety of IGV-001 in subjects with ndGBM across 20 sites in the United States. After surgical resection, subjects were randomized 2:1 and treated with IGV-001 or placebo followed by SOC. The primary outcome is PFS, defined as the time from randomization to first progression, as determined by blinded central radiology review, or death. Secondary outcomes include OS, defined as the time from randomization to death due to any cause, and safety. As of May 22, 2024, 99 subjects were randomized and 95 implanted with IGV-001 or placebo plus SOC. A total of 39/45 (86.7%) subjects had sufficient follow-up time after initiated treatment with concurrent radiation and temozolomide. Nine of 72 randomized (12.5%) discontinued treatment, including 7 who stopped during the SOC treatment period. None ceased treatment for adverse events, protocol deviations, or death. A total of 11/72 (15.3%) randomized subjects discontinued the study after randomization. A review of blinded safety data did not show any emerging risk and supports no change to the benefit-risk profile of IGV-001 versus placebo. Updated data will be presented.
Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer
Hamilton, Phineas T. , Phung, Minh Tung , Stevens, Donald L.I., Kalaria, Shreena , Laumont, Céline M. , Moss, Elena, Alimujiang, Aliya , Meagher, Nicola S. , Hendley, Joy , Goode, Ellen L. , Shen, Hui , Richardson, Jean , Deurloo, Cindy McKinnon, Chase, Anne, Grout, Bronwyn, Cushing‐Haugen, Kara L. , Anglesio, Michael S. , Huntsman, David G. , Talhouk, Aline , Hanley, Gillian E. , Alsop, Jennifer , Jimenez-Linan, Mercedes , Boros, Jessica , Brand, Alison H. , Sharma, Raghwa , Hecht, Jonathan L. , Sasamoto, Naoko , Terry, Kathryn L. , Lester, Jenny, Carney, Michael E. , Goodman, Marc T. , Fasching, Peter A., Bisinotto, Christiani, Le, Nhu D. , Menon, Usha , García, María J. , Rodríguez‐Antona, Cristina , Farrington, Kyo , Kelemen, Linda E. , Kommoss, Stefan , Staebler, Annette , Garsed, Dale W. , Piskorz, Anna , Bowtell, David D.L. , Ramus, Susan J. , Pike, Malcolm C., Pearce, Celeste Leigh , Ramus, Susan J , Rodríguez-Antona, Cristina , Menon, Usha , Anglesio, Michael S , Brand, Alison H , Bowtell, David D , Garsed, Dale W , Goodman, Marc T , Phung, Minh Tung , Nelson, Brad H. , Milne, Katy , Harris, Bronwyn, Thornton, Shelby , Singh, Karanvir , Bolithon, Adelyn , Fereday, Sián , Kennedy, Catherine J. , Ariyaratne, Dinuka , Alsop, Kathryn , Traficante, Nadia , Karnezis, Anthony N. , Chase, Anne, Doherty, Jennifer A. , Harris, Holly R. , Heinze, Karolin , Pharoah, Paul D.P. , Harnett, Paul R. , Karlan, Beth Y. , Hernandez, Brenda Y. , Wilkens, Lynne R. , Behrens, Sabine , Fortner, Renée T. , Reis, Francisco José Cândido dos , Ghatage, Prafull , Köbel, Martin , Elishaev, Esther , Modugno, Francesmary , Cook, Linda S. , Gentry‐Maharaj, Aleksandra , Brenton, James D. , DeFazio, Anna

Mayo Clinic

Journal of Clinical Investigation | October 29, 2024 | Volume: 134 | Issue: 24 | Pages: No page available

10.1172/jci179501 | PMID 39470729 Get It

BACKGROUND Despite an overall poor prognosis, about 15% of patients with advanced-stage tubo-ovarian high-grade serous carcinoma (HGSC) survive 10 or more years after standard treatment. METHODS We evaluated the tumor microenvironment of this exceptional, understudied group using a large international cohort enriched for long-term survivors (LTS; 10+ years; n = 374) compared with mid-term (MTS; 5–7.99 years; n = 433) and short-term survivors (STS; 2–4.99 years; n = 416). Primary tumor samples were immunostained and scored for intraepithelial and intrastromal densities of 10 immune-cell subsets (including T cells, B cells, plasma cells, myeloid cells, PD-1 + cells, and PD-L1 + cells) and epithelial content. RESULTS Positive associations with LTS compared with STS were seen for 9 of 10 immune-cell subsets. In particular, the combination of intraepithelial CD8 + T cells and intrastromal B cells showed near 5-fold increased odds of LTS compared with STS. All of these associations were stronger in tumors with high epithelial content and/or the C4/Differentiated molecular subtype, despite immune-cell densities generally being higher in tumors with low epithelial content and/or the C2/Immunoreactive molecular subtype. CONCLUSION The tumor microenvironment of HGSC LTS is distinguished by the intersection of T and B cell coinfiltration, high epithelial content, and C4/differentiated molecular subtype, features which may inspire new approaches to immunotherapy. FUNDING Ovarian Cancer Research Program (OCRP) of the Congressionally Directed Medical Research Program (CDMRP), U.S. Department of Defense (DOD); American Cancer Society; BC Cancer Foundation; Canada’s Networks of Centres of Excellence; Canadian Cancer Society; Canadian Institutes of Health Research; Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania, Cancer Foundation of Western Australia; Cancer Institute NSW; Cancer Research UK; Deutsche Forschungsgesellschaft; ELAN Funds of the University of Erlangen-Nuremberg; Fred C. and Katherine B. Andersen Foundation; Genome BC; German Cancer Research Center; German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research; Instituto de Salud Carlos III; Mayo Foundation; Minnesota Ovarian Cancer Alliance; Ministerio de Economía y Competitividad; Medical Research Council (MRC); National Center for Advancing Translational Sciences; National Health and Medical Research Council of Australia (NHMRC); Ovarian Cancer Australia; Peter MacCallum Foundation; Sydney West Translational Cancer Research Centre; Terry Fox Research Institute; The Eve Appeal (The Oak Foundation); UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge; University of Pittsburgh School of Medicine; U.S. National Cancer Institute of the National Institutes of Health; VGH & UBC Hospital Foundation; Victorian Cancer Agency.